We are live on ! Find out more
GILD icon

Gilead Sciences

1,439 hedge funds and large institutions have $120B invested in Gilead Sciences in 2014 Q4 according to their latest regulatory filings, with 216 funds opening new positions, 604 increasing their positions, 518 reducing their positions, and 90 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more first-time investments, than exits

New positions opened: 216 | Existing positions closed: 90

17% more repeat investments, than reductions

Existing positions increased: 604 | Existing positions reduced: 518

8% more funds holding

Funds holding: 1,3271,439 (+112)

13% less capital invested

Capital invested by funds: $139B → $120B (-$18.6B)

18% less funds holding in top 10

Funds holding in top 10: 240196 (-44)

32% less call options, than puts

Call options by funds: $3.07B | Put options by funds: $4.55B

Holders
1,439
Holders Change
+112
Holders Change %
+8.44%
% of All Funds
38.36%
Holding in Top 10
196
Holding in Top 10 Change
-44
Holding in Top 10 Change %
-18.33%
% of All Funds
5.23%
New
216
Increased
604
Reduced
518
Closed
90
Calls
$3.07B
Puts
$4.55B
Net Calls
-$1.48B
Net Calls Change
-$53.3M
Name Holding Trade Value Shares
Change
Change in
Stake
EAM
326
Edge Asset Management
Washington
$23M -$5.4M -52,220 -18%
AAP
327
Ardsley Advisory Partners
Connecticut
$23M -$45.2M -436,900 -64%
PMAM
328
Picton Mahoney Asset Management
Ontario, Canada
$23M +$25.2M +243,600 New
BC
329
Bartlett & Co
Ohio
$22.6M +$209K +2,018 +0.8%
B
330
Baird
Wisconsin
$22.5M +$8.62M +83,320 +54%
BPBT
331
Boston Private Bank & Trust
Massachusetts
$22.4M -$269K -2,601 -1%
PAI
332
Palo Alto Investors
California
$22.1M +$6.94M +67,100 +40%
RHBC
333
R.H. Bluestein & Co
Michigan
$21.7M -$1.79M -17,342 -7%
IAM
334
Impax Asset Management
New Hampshire
$21.7M -$3.49M -33,735 -13%
EAM
335
EverPoint Asset Management
Connecticut
$21.7M +$23.8M +230,000 New
Janney Montgomery Scott
336
Janney Montgomery Scott
Pennsylvania
$21.4M +$9.28M +89,679 +65%
NIM
337
Needham Investment Management
New York
$21.4M
Artisan Partners
338
Artisan Partners
Wisconsin
$21.4M -$1.65M -15,915 -7%
Robeco Institutional Asset Management
339
Robeco Institutional Asset Management
Netherlands
$21.2M +$13.9M +134,216 +148%
Zurich Cantonal Bank
340
Zurich Cantonal Bank
Switzerland
$21.1M +$6.25M +60,458 +37%
Cohen & Steers
341
Cohen & Steers
New York
$21.1M +$6.37M +61,600 +38%
NPPM
342
North Point Portfolio Managers
Ohio
$21M +$362K +3,500 +2%
MC
343
Muhlenkamp & Co
Pennsylvania
$20.6M +$1.3M +12,595 +6%
CIM
344
Contravisory Investment Management
Massachusetts
$20.5M -$820K -7,925 -4%
FLPIM
345
F.L. Putnam Investment Management
Massachusetts
$20.4M +$2.43M +23,471 +12%
BPC
346
Banque Pictet & Cie
Switzerland
$20M -$2.87M -27,720 -12%
SG
347
Swarthmore Group
Pennsylvania
$20M -$18.9M -182,375 -46%
CFB
348
Cullen/Frost Bankers
Texas
$19.9M -$1.16M -11,200 -5%
ZIC
349
ZWJ Investment Counsel
Georgia
$19.7M +$418K +4,044 +2%
AIA
350
Avalon Investment & Advisory
Texas
$19.6M +$1.92M +18,539 +10%

GILD Hedge Fund Activity: Q4 2014 in Review

1,439 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q4 2014, worth a combined $120B — down 13% from $139B a quarter earlier.

Buyers outnumbered sellers: 216 funds opened new GILD positions and 90 closed out — a net gain of 126 holders — while 604 added to existing stakes and 518 trimmed.

The largest buyer was Temasek Holdings, adding an estimated $811M. The largest seller was Capital Research Global Investors, cutting an estimated $2.53B.

  • 1,439 institutional investors held Gilead Sciences (GILD) as of Q4 2014, up from 1,327 in Q3 2014.
  • Funds reported $120B of Gilead Sciences stock for Q4 2014, down 13% quarter-over-quarter.
  • 216 funds opened new Gilead Sciences positions in Q4 2014 and 90 closed out, a net change of +126 holders.
  • The largest Gilead Sciences buyer in Q4 2014 was Temasek Holdings, an estimated $811M added.
  • The largest Gilead Sciences seller in Q4 2014 was Capital Research Global Investors, an estimated $2.53B sold.

Based on aggregated 13F filings for Q4 2014.